Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-13. Numbers and descriptions here follow the published literature rather than marketing material.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
==== Connective tissue fibers ==== The arrangement of connective tissue fibers determines the range of motion of a body, and serves as an antagonist against muscle contraction. The most commonly observed connective tissue arrangement for soft bodied animals consists of layers of alternating right and left-handed helices of connective tissue fibers which surround the hydraulic body. This cross helical arrangement is seen in the tube feet starfish, different types of worms and suckers in octopus. This cross helical arrangement allows for the connective tissue layers to evenly distribute force throughout the hydrostatic body. Another commonly observed connective tissue fiber range is when the connective tissue fibers are embedded within a muscle layer. This arrangement of connective tissue fibers creates a stiffer body wall and more muscle antagonism, which allows for more elastic force to be generated and released during movement. This fiber arrangement is seen in the mantle of squid and the fins in sharks.
Additionally, ketone bodies can be anti-inflammatory. Some kinds of cancer cells are unable to use ketone bodies, as they do not have the necessary enzymes to engage in ketolysis. It has been proposed that actively engaging in behaviors that promote ketogenesis could help manage the effects of some cancers.
== Capture of Constantinople == When the Nicaean force reached the village of Selymbria, some 30 miles (48 km) west of Constantinople, they learned from some independent local farmers (thelematarioi) that the entire Latin garrison, as well as the Latin-allied Venetian fleet, was absent conducting a raid against the Nicaean island of Daphnousia in the Black Sea. Strategopoulos initially hesitated to take advantage of the situation, fearing that his small force might be destroyed if the Latin army returned too soon, and because he would exceed the provisions of the emperor's orders, but eventually decided he could not squander such a remarkable opportunity to seize the city without a prolonged siege.
== Chemical structure == Gaseous methylglyoxal has two carbonyl groups: an aldehyde and a ketone. In the presence of water, it exists as hydrates and oligomers. The formation of these hydrates is indicative of the high reactivity of MGO, which is relevant to its biological behavior.
== Overview == The ribosomal P-site plays a vital role in all phases of translation. Initiation involves recognition of the start codon (AUG) by initiator tRNA in the P-site, elongation involves passage of many elongator tRNAs through the P site, termination involves hydrolysis of the mature polypeptide from tRNA bound to the P-site, and ribosome recycling involves release of deacylated tRNA. Binding a tRNA to the P-site in the presence of mRNA establishes codon-anticodon interaction, and this interaction is important for small subunit ribosome (30S) contacts to the tRNA. The classical two-state model proposes that the ribosome contains two binding sites for tRNA, P-site and A-site. The A-site binds to incoming aminoacyl-tRNA which has the anti-codon for the corresponding codon in the mRNA presented in the A-site. After peptide formation between the C-terminal carbonyl group of the growing polypeptide chain (attached to a P-site bound tRNA) and the amino group of the aminoacyl-tRNA (A-site bound), the polypeptide chain is then attached to the tRNA in the A-site. The deacylated tRNA remains in the P-site and is released once the peptidyl-tRNA is transferred to the P-site. How is the translocation of the peptidyl-tRNA from the A-site to the P-site achieved to complete the cycle? It was proposed that this is done in two steps by the movement of the two ribosomal subunits with respect to each other, with the formation of an intermediate hybrid structure: the A-site of one subunit with the P-site of the other subunit.
Sources: en.wikipedia.org
== Differences in structure and subunit composition between species == In all organisms, PDC is a large complex composed of multiple copies of the three catalytic subunits E1, E2 and E3. Another common feature of all PDCs is the fact that the subunit E2 forms the core of the complex to which the peripheral subunits E1 and E3 bind. Eukaryotic PDCs contain an additional, non-catalytic subunit in the core termed E3 binding protein (E3BP) (sometimes also "protein X"). In PDCs with a hetero-oligomeric core with multiple copies of E2 and E3BP, E1 exclusively associates with E2, and E3 only binds to E3BP. In contrast, E1 and E3 compete for binding to E2 in bacterial PDCs with a homo-oligomeric E2 core. While the peripheral enzyme E3 is a homodimer in all organisms, the peripheral enzyme E1 is an alpha2beta2 heterotetramer in eukaryotes.
== Chemistry == Desglymidodrine, also known as 2,5-dimethoxy-β-hydroxyphenethylamine, is a substituted phenethylamine derivative. Midodrine's experimental log P is -0.5 and its predicted log P ranges from -0.49 to -0.95. The predicted log P of desglymidodrine ranges from -0.01 to 0.15.
== April 1942-May 1943 == The division was assigned to XXXXVIII Panzer Corps during the opening phases of Fall Blau (Case Blue), the Wehrmacht's 1942 strategic summer offensive in southern Russia. During the combined Soviet winter offensives Operation Uranus and Operation Mars in late November through mid-December, the division fought near Rzhev, where it was rendered combat ineffective. Called upon to deal with one crisis after another, the division came to be known as die Feuerwehr (the Fire Brigade). By 18 November 1942, the division only had seven Panzer II light tanks, one Panzer III and nineteen Panzer IV medium tanks, and three Sd.Kfz. 265 Panzerbefehlswagen command tanks operational. In January–February 1943, Großdeutschland and XXXXVIII Panzer Corps, along with the II SS Panzer Corps took part in the Third Battle of Kharkov. The division had 5 Panzer IIs, 20 Panzer IIIs, 85 Panzer IVs, 9 Tiger I heavy tanks, 2 Panzerbefehlswagens, and 26 Flammpanzer III flamethrower tank variants of the Panzer III available at that time. The division fought alongside the 1. SS Division Leibstandarte SS Adolf Hitler, 2. SS Division Das Reich and 3. SS Division Totenkopf during these battles. The division's losses as total write-offs at that time amounted to one Panzer III, twelve Panzer IVs, and one Tiger I. After the capture of Kharkov, the Großdeutschland was again pulled back and refitted.
== Chemistry == Expired tetracyclines or tetracyclines allowed to stand at a pH less than 2 are reported to be nephrotoxic due to the formation of a degradation product, anhydro-4-epitetracycline causing Fanconi syndrome. In the case of doxycycline, the absence of a hydroxyl group in C-6 prevents the formation of the nephrotoxic compound. Nevertheless, tetracyclines and doxycycline itself have to be taken with caution in patients with kidney injury, as they can worsen azotemia due to catabolic effects.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.